Skip to main content

Table 3 Efficacy outcomes

From: Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Outcome Vemurafenib (N = 46)
Confirmed BORR, n (%) [95% CI] 24 (52.2) [36.95–67.11]
 Complete response 1 (2.2)
 Partial response 23 (50.0)
 Stable disease 21 (45.7)
 Progressive disease 1 (2.2)
 Disease control rate 45 (97.8)
Median time to confirmed response, months (range) 1.84 (1.7–5.7)
Median duration of confirmed response, months (95% CI) 9.13 (7.39–NE)
Median PFS, months (95% CI) 8.25 (5.65–10.94)
PFS, % (95% CI)
 6 months 58.7 (44.5–72.9)
 1 year 33.4 (19.5–47.4)
Median OS, months (95% CI) 13.54 (12.19–NE)
OS, % (95% CI)
 6 months 89.1 (80.1–98.1)
 1 year 64.6 (50.7–78.6)
  1. BORR best overall response rate, CI confidence interval, NE not estimable, PFS progression-free survival, OS overall survival